More Than One-Third of Cancer Trials Disrupted by Pandemic Are Resuming
Approximately 37.8 percent of more than 350 cancer trials worldwide that were disrupted by COVID-19 have since resumed, according to a report by life sciences analytics firm GlobalData. The report noted that this represents the largest proportion of trials that have resumed since the pandemic began.
The U.S., with the largest proportion of active oncology trials as well as the largest number of COVID-19 cases, had the most trials disrupted (41.8 percent) but also the most trials resumed (41.6 percent). The UK tied with Spain on the third-largest number of disrupted oncology trials at 7 percent, but its comeback rate of 10.7 percent passed that of second-place France, which had a disruption rate of 8 percent but a recovery rate of only 9.7 percent. Spain’s recovery rate was 7.2 percent.
Solid tumor studies account for the largest proportion of trials resumed since the start of the COVID-19 disruptions (20.7 percent), according to GlobalData. Across all disease therapies, GlobalData reported that the number of total disrupted clinical trials started to decrease around June. Trials that suspended enrollment were the only studies that “have been on a downward trajectory,” the report said.
The report noted that trials that began recruitment and had chosen their sites and investigators before COVID-19 are having more success with resuming their trials, but only if their enrollment wasn’t impacted by the pandemic.
To read the report, click here: https://bit.ly/3aXAZzP.